Thomas Zech Email & Phone Number

Retired senior financial executive with over 25 years of experience in public and private pharma/biotech companies. Expertise in corporate governance, financial reporting and public and private fund raising activities. Open to early-stage company board and advisory opportunities.

Chief Financial Officer of MEI Pharma, a San Diego based oncology company focused on the clinical development of novel anti-cancer therapeutics.

Providing financial and accounting advisory services to development stage and commercial life science and technology companes.* Private equity/venture equity and IPO* Licensing and business development* M&A (acquistions, mergers, divestitures, and restructuring)* Management of Finance, Distribution/Supply Chain, IT and Human Resources* Experienced in multi-site and muti-product manufacturing and distribution environments* Sarbanes-Oxley (internal controls)* Financial reporting (SEC) including domestic and foreign consolidations* Auditing, tax compliance, US GAAP and IFRS

SkyePharma Inc. was renamed Pacira Pharmaceuticals, Inc upon divestiture by SkyePharma PLC in March 2007. SkyePharma Inc. was a subsidiary of SkyePharma PLC, a publicly traded (NASD:SKYE; LSE:SKP) London based drug delivery company, with operations in the U.S., Canada, France and Switzerland. San Diego operations include development and manufacture of extended release injectable pharmaceuticals sold in the US and EU. * Member of the Executive Team responsible for leadership of finance/accounting, IT and EH&S groups* Key participant in M&A, licensing and deal structuring * Consolidation of North American operations of SkyePharma, financial reporting, budgeting and planning. SOX compliance, IFRS, and US GAAP* Completed private equity financing for $85 million* Negotiated venture debt deal - $10 million* Strategic planning and goal setting* Tax compliance and reporting* International sales and distribution, revenue recognition and cost accounting* Due diligence and contract compliance

A leading manufacturer and supplier of molecular biology supplies, reagents and equipment worldwide (revenues of $90 million).The organization was comprised of 23 privately held companies with locations in California, Wyoming, Texas and Amsterdam. Acquired by Agilent Technologies.* Responsible for multi-site accounting and finance departments * Consolidated and reported world-wide results including management of currency hedging strategy* Implemented improved working capital controls, increasing cash flow* Implemented and reported complex domestic and international tax structure

A publicly traded (NASD:ATIS) company, which was a leader in research, development and manufacture of living human tissue products for wound healing and transplantation. Products were acquired by UK partner Smith & Nephew.• Participated in multiple follow-on financings, raising over $100 million• Developed and implemented a cost accounting system for the first commercial product. * Key participant in the selection and implementation of a MRP system (QAD)• Responsible for joint venture accounting with UK partner (Smith & Nephew

Mba, Finance

MBA with concentration in finance.

Bs, Accounting

BS with concentration in accounting.